Clinical factors affecting prognosis of limb osteosarcoma in China: a multicenter retrospective analysis.


Journal

The Journal of international medical research
ISSN: 1473-2300
Titre abrégé: J Int Med Res
Pays: England
ID NLM: 0346411

Informations de publication

Date de publication:
Aug 2020
Historique:
entrez: 1 9 2020
pubmed: 1 9 2020
medline: 15 5 2021
Statut: ppublish

Résumé

This study was performed to explore the relationship between various clinical factors and the prognosis of limb osteosarcoma. We retrospectively analyzed the clinical data of 336 patients with limb osteosarcoma treated from June 2000 to August 2016 at 7 Chinese cancer centers. Data on the patients' clinical condition, treatment method, complications, recurrences, metastasis, and prognosis were collected and analyzed. Kaplan-Meier analysis and Cox regression models were used to analyze the data. The patients comprised 204 males and 132 females ranging in age from 6 to 74 years (average, 21.1 years). The overall 3- and 5-year survival rates were 65.0% and 55.0%, respectively. The 5-year overall survival rate was 64.0% with standard chemotherapy and 45.6% with non-standard chemotherapy. Cox regression analysis demonstrated that standard chemotherapy, surgery, recurrence, and metastasis were independent factors associated with the prognosis of limb osteosarcoma. The survival of patients with limb osteosarcoma can be significantly improved by combining standard chemotherapy and surgery. The overall survival rate can also be improved by adding methotrexate to doxorubicin-cisplatin-ifosfamide triple chemotherapy.

Identifiants

pubmed: 32865070
doi: 10.1177/0300060520920053
pmc: PMC7469730
doi:

Substances chimiques

Doxorubicin 80168379AG
Cisplatin Q20Q21Q62J
Ifosfamide UM20QQM95Y
Methotrexate YL5FZ2Y5U1

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

300060520930856

Références

Surg Oncol. 2010 Dec;19(4):193-9
pubmed: 19515554
Orphanet J Rare Dis. 2007 Jan 23;2:6
pubmed: 17244349
Clin Orthop Relat Res. 2010 Nov;468(11):2854-9
pubmed: 20559766
CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
pubmed: 24890451
J Pediatr Surg. 2006 Jan;41(1):194-9
pubmed: 16410132
J Clin Oncol. 2012 Jun 10;30(17):2112-8
pubmed: 22564997
Ann Oncol. 2010 May;21 Suppl 5:v204-13
pubmed: 20555083
J Clin Oncol. 2005 Mar 20;23(9):2004-11
pubmed: 15774791
Pediatr Blood Cancer. 2010 Jul 1;54(7):990-9
pubmed: 20135700
Pediatr Blood Cancer. 2009 Mar;52(3):340-5
pubmed: 19021220
Surg Oncol. 2015 Mar;24(1):9-15
pubmed: 25453577
Eur J Cancer. 2003 Mar;39(4):488-94
pubmed: 12751380
J Orthop Sci. 2009 Sep;14(5):556-65
pubmed: 19802667
Cancer Treat Res. 2009;152:3-13
pubmed: 20213383
J Cancer Res Clin Oncol. 2010 Apr;136(4):561-70
pubmed: 19784847
J Pediatr Hematol Oncol. 2006 Dec;28(12):774-80
pubmed: 17164644
J Clin Oncol. 1988 Feb;6(2):329-37
pubmed: 2448428
Cancer. 2009 Apr 1;115(7):1531-43
pubmed: 19197972
Cancer Metastasis Rev. 2009 Jun;28(1-2):247-63
pubmed: 19214708
Int J Cancer. 2015 Apr 15;136(8):1921-30
pubmed: 25242378
Orthop Clin North Am. 1996 Jul;27(3):473-81
pubmed: 8649730
Asia Pac J Clin Oncol. 2011 Sep;7(3):270-5
pubmed: 21884438
Cancer. 1979 Jun;43(6):2163-77
pubmed: 88251
Cancer Treat Res. 2009;152:239-62
pubmed: 20213394
J Clin Oncol. 2005 Jan 20;23(3):559-68
pubmed: 15659502
Clin Orthop Relat Res. 2014 Oct;472(10):3188-95
pubmed: 24980644
Cancer Treat Res. 2009;152:219-37
pubmed: 20213393
Paediatr Drugs. 2008;10(5):315-27
pubmed: 18754698
Cancer. 2013 Oct 15;119(20):3727-36
pubmed: 23907996
J Chemother. 2004 Dec;16(6):582-8
pubmed: 15700851

Auteurs

Jia Han (J)

Department of Orthopedics, PLA 960th Hospital, Jinan City, Shandong Province, China.

Yiyang Yu (Y)

Department of Bone Oncology, Hebei Medical University Third Affiliated Hospital, Shijiazhuang, Hebei, China.

Sujia Wu (S)

Department of Orthopedics, East Region Military Command General Hospital, Nanjing, Jiangsu, China.

Zhen Wang (Z)

Department of Bone Oncology, Xijing Hospital, Xian, Shaanxi, China.

Weibin Zhang (W)

Department of Orthopaedics, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China.

Ming Zhao (M)

Department of Bone Oncology, Hebei Medical University Third Affiliated Hospital, Shijiazhuang, Hebei, China.

Yang Yao (Y)

Department of Oncology, Shanghai 6th People's Hospital Affiliated to Shanghai Jiao Tong University School, Shanghai, China.

Yongcheng Hu (Y)

Department of Bone Oncology, Tianjin Hospital, Tianjin, China.

Wenjian Wang (W)

Department of Orthopedics, PLA 960th Hospital, Jinan City, Shandong Province, China.

Xiaozhou Liu (X)

Department of Orthopedics, East Region Military Command General Hospital, Nanjing, Jiangsu, China.

Wenxi Yu (W)

Department of Oncology, Shanghai 6th People's Hospital Affiliated to Shanghai Jiao Tong University School, Shanghai, China.

Jie Cheng (J)

Department of Bone Oncology, Xijing Hospital, Xian, Shaanxi, China.

Lili Yu (L)

Department of Information, PLA 960th Hospital, Jinan, Shandong, China.

Qiyuan Bao (Q)

Department of Orthopaedics, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China.

Guochuan Zhang (G)

Department of Bone Oncology, Hebei Medical University Third Affiliated Hospital, Shijiazhuang, Hebei, China.

Xiuchun Yu (X)

Department of Orthopedics, PLA 960th Hospital, Jinan City, Shandong Province, China.

Ruoxian Song (R)

Department of Orthopedics, PLA 960th Hospital, Jinan City, Shandong Province, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH